BrainScope
BrainScope is a Maryland-based medical neurotechnology company that develops and commercializes a handheld, FDA-cleared AI/ML-enabled EEG device and disposable headsets for objective assessment of mild traumatic brain injury, concussion, and emerging CNS biomarkers for U.S. hospitals, the Department of Defense, and biopharma research customers.
- Company typePrivate
- Founded2010
- HeadquartersBethesda, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BrainScope does
BrainScope is a private, Maryland-based medical neurotechnology company that develops and commercializes a handheld, FDA-cleared AI/ML-enabled EEG device (BrainScope One) and accompanying disposable electrode headsets for objective assessment of mild traumatic brain injury and concussion. The device runs proprietary AI-derived algorithms (Structural Injury Classifier, Brain Function Index, and Concussion Index) on EEG signals to identify likely brain bleeds (99% sensitivity to intracranial blood of at least 1 mL, 98% NPV) and concussions (86% sensitivity, 71% specificity, 90% NPV in JAMA Network Open 2021 validation), with results designed for upload to the electronic medical record. BrainScope's primary commercial segments are U.S. hospital emergency departments, urgent care, and U.S. Department of Defense / federal customers (sold via RedOne Medical SDVOSB channel with NSN-listed device and headset), with secondary use in collegiate and high school athletic programs.
The company generates revenue through one-time sales of the BrainScope hardware under quote-based purchase orders with net-30 terms and recurring sales of single-use disposable electrode headsets, supplemented by extended warranty and post-sale support. In June 2025, BrainScope launched its Large Neural Model Platform, an in-house LLM-style deep learning foundation model applied to EEG, intended to enable a pipeline of new CNS biomarkers for Alzheimer's disease, ARIA detection, stroke, and clinical trial enrichment, funded in part by the Alzheimer's Drug Discovery Foundation. Recent strategic emphasis is on scaling commercialization under a new CEO (Matt Adams, Nov 2025), new VP of Sales (David Wingate, 2026), and an expanded Board including ex-Medtronic and Aon representation.
The company has raised approximately $35 million from Aon plc (2021) plus prior grants and equity from Maryland Venture Fund, NFL/GE, Revolution (Steve Case), and ADDF, and has accumulated more than $27 million in U.S. Department of Defense research contracts. BrainScope holds 83 issued patents, 10 FDA and global clearances, and is led from its Rockville, Maryland headquarters.
BrainScope firmographics
Firmographics- Name
- BrainScope
- Legal name
- BrainScope Company Inc
- Website
- https://brainscope.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BrainScope is a Maryland-based medical neurotechnology company that develops and commercializes a handheld, FDA-cleared AI/ML-enabled EEG device and disposable headsets for objective assessment of mild traumatic brain injury, concussion, and emerging CNS biomarkers for U.S. hospitals, the Department of Defense, and biopharma research customers.
- Ownership category
- akta.pro rank
BrainScope industry classification
Industry- Product category
- EEG-based Brain Injury Diagnostic Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
- akta.pro secondary industry
- Neurology Telemedicine Platforms (HLALAGAC)
Keywords
Where BrainScope is headquartered
LocationHeadquarters
- HQ city
- Bethesda
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BrainScope business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Hardware sales of BrainScope EEG device (Equipment): One-time sale of the proprietary BrainScope device (BrainScope 500 Series / BrainScope One) shipped Ex Works (INCOTERMS 2020) under purchase orders; pricing quote-based with net-30 invoice terms.
- Consumables: disposable electrode headsets: Recurring revenue from disposable electrode headsets (e.g., Part # AH-3125, Box of 25; NSN 6515-01-665-4357) used with the BrainScope device for each patient assessment.
- Extended warranty and post-sale support: Customers may purchase an extended warranty to lengthen the limited 1-year product warranty for Equipment beyond the first year post-delivery; per Standard Purchase Terms.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based enterprise sale of device + consumables under Standard Purchase Terms |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels10 records
BrainScope product offering
Product offeringCore offering
BrainScope develops and commercializes FDA-cleared, AI/ML-enabled handheld EEG medical devices and proprietary biomarkers for objective assessment of traumatic brain injury (brain bleeds and concussions) at the point of care. Its flagship product, BrainScope One, pairs a ruggedized handheld EEG capture device and disposable electrode headsets with on-device algorithms (Structural Injury Classifier, Concussion Index, Brain Function Index). The company also operates a Large Neural Model deep learning platform extending LLM-style architectures to EEG to develop biomarkers across CNS indications including Alzheimer's disease prediction, stroke, and ARIA monitoring.
Product overview
BrainScope offers a single unified product — BrainScope One — a handheld, FDA-cleared AI/ML medical device for objective head injury assessment, augmented by a platform-plus-modules architecture. The core hardware device hosts a suite of proprietary AI-derived EEG algorithms (Structural Injury Classifier, Concussion Index, and Brain Function Index) along with digitized neurocognitive assessments (SCAT5, MACE2, PECARN, NPC), and pairs with a disposable electrode headset accessory. Underpinning future biomarker development is the Large Neural Model Platform, a deep learning platform that applies LLM-style architectures to EEG data and currently powers research efforts such as an early Alzheimer's prediction biomarker. Together, the BrainScope One device, its on-device AI modules, the disposable headset, and the Large Neural Model platform form an integrated EEG-based brain assessment and biomarker discovery offering targeted at clinical, military, and research users.
Differentiator
Problem solved
Functional benefit
Brands
- BrainScope One: Flagship FDA-cleared, hand-held, EEG-based medical device for rapid, non-invasive assessment of traumatic brain injury and concussion at the point of care, intended for use in hospital emergency departments, urgent care centers, and other clinical settings.
Products and services
- BrainScope One
- BrainScope Disposable Electrode Headset
- Large Neural Model Platform
- Early Alzheimer's Prediction Biomarker (Proof-of-Concept)
Quantifiable outcome
- ~50% reduction in unnecessary head CTs reported across major U.S. health systems
- +7 more outcomes
Companies that use BrainScope
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles5 records
BrainScope technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability6 records
Feature8 records
BrainScope partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered strategic advisor (board-level), strategic advisor (board chairman), clinical society endorsement / alignment, core channel partner (federal / military) and research collaboration partner.
- Medtronic (Board representation - Mike Genau)strategic advisor (board-level)Mike Genau, former President of Medtronic's Americas Region (a $7B business unit), joined BrainScope's Board of Directors in June 2025, bringing MedTech scaling and commercial strategy expertise.
- Ralph Terkowitz (Board Chairman)strategic advisor (board chairman)Ralph Terkowitz, former General Partner at ABS Capital Partners, elected Chairman of BrainScope's Board in June 2025 (previously on the Board since 2023). Also serves on the Board of The 10,000 Brains Project and is Co-Chairman of The Robert Packard Center for ALS Research at Johns Hopkins.
- ACEP (American College of Emergency Physicians) Choosing Wisely Campaignclinical society endorsement / alignmentBrainScope's technology 'supports the American College of Emergency Physicians (ACEP) Choosing Wisely® campaign to avoid CT scans of the head in emergency department patients with minor head injury' (per 2021 JAMA release). CMS CQM #415 is also used to align messaging around head CT reduction.
- RedOne Medical (SDVOSB)core channel partner (federal / military)CVE-certified Service-Disabled Veteran-Owned Small Business that sources innovative medical devices and pharmaceuticals for the federal marketplace. Lists BrainScope Device 500 Series (Part # BSO-2001, NSN 6515-01-655-4480) and Disposable Electrode Headsets (Part # AH-3125, NSN 6515-01-665-4357). Cage Code 71UG3; ECAT, DAPA, VA FSS in progress.
- University of Rochester / Lead academic investigators (Concussion Index validation)research collaboration partnerLead author Dr. Jeffrey Bazarian (Department of Emergency Medicine, University of Rochester School of Medicine) led the JAMA Network Open 2021 study; Dr. Leslie Prichep, CSO of BrainScope, co-authored. Studies conducted 2017-2019 across 49 high schools, colleges, and concussion clinics.
Scale indicators15 records
Recent moves6 records
Expansion highlights7 records
BrainScope competitors and assessment
Company assessmentDirect peers
- Ceribell: Ceribell develops AI-enabled point-of-care EEG devices for hospital use (including emergency and ICU settings) for rapid brain monitoring and seizure detection. Directly comparable to BrainScope as a fellow AI-EEG neurology medical device company targeting U.S. health systems with FDA-cleared hardware and cloud-connected software.
- Wave Neuroscience (formerly Mind Research Network / Neuropathix): Wave Neuroscience offers EEG-based diagnostic and treatment platforms for brain injury, PTSD, and other neurological conditions. Comparable to BrainScope as a direct competitor in the EEG-based brain health and head injury assessment space with overlapping clinical indications.
Broad incumbents
- Natus Medical: Natus Medical is a long-established neurodiagnostic medical device company offering a broad portfolio of EEG, EMG, and sleep diagnostic equipment to hospitals and clinics. Comparable to BrainScope as an incumbent in the same neurology/EEG device category serving U.S. health systems, though with a much wider product portfolio.
- Compumedics: Compumedics manufactures EEG, sleep diagnostic, and brain monitoring equipment used in hospitals and research settings globally. Comparable to BrainScope as an established neurodiagnostics player with overlapping EEG hardware and clinical applications.
- Cadwell Industries: Cadwell is a privately held neurodiagnostic device maker offering EEG, EMG, and intraoperative monitoring products to hospitals and neurology practices. Comparable to BrainScope as an EEG-focused neurology device company serving similar hospital and clinical customers.
- Medtronic: Medtronic is a global MedTech leader with a significant neuroscience division (formerly Covidien) covering brain monitoring, neuromodulation, and neurosurgery. BrainScope's VP Sales and Board member both came from Medtronic, underscoring Medtronic as a relevant benchmark and potential strategic acquirer or competitor in the neurodiagnostics space.
- GE HealthCare: GE HealthCare is a major medical imaging and diagnostics company with EEG and patient monitoring offerings, and through the GE-NFL Head Health Challenge has been a direct grant partner to BrainScope. Comparable as a broader incumbent in hospital neurodiagnostics that could compete or partner with BrainScope's AI-EEG platform.
- Philips (Royal Philips): Philips offers a portfolio of patient monitoring and neurology solutions (including EEG) to hospitals globally. Comparable to BrainScope as a large incumbent with overlapping neurodiagnostic hospital sales channels and the ability to bundle EEG into broader capital sales.
Emerging players
- iRhythm Technologies: iRhythm Technologies applies AI/ML to cardiac ambulatory monitoring (Zio patch), demonstrating a parallel commercial playbook of combining a proprietary wearable sensor with cloud-based AI diagnostics in a hospital-prescribed workflow. Conceptually comparable to BrainScope's hardware-plus-AI biomarker model, though in cardiology rather than neurology.
- Emotiv: Emotiv develops consumer and research-grade EEG headsets with cloud-based AI analytics for brain-computer interface and wellness applications. Comparable to BrainScope as an EEG hardware-plus-AI platform player, though serving research and consumer segments rather than the FDA-regulated clinical market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
BrainScope social profiles
Digital presenceBrainScope financial estimates
Financial estimateRevenue estimate
Valuation estimate
BrainScope leadership team
Management profileNumber of profiles
Profiles11 records
BrainScope funding detail
Funding detailFunding overview
Funding rounds13 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BrainScope M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BrainScope
What does BrainScope do?
BrainScope develops and commercializes FDA-cleared, AI/ML-enabled handheld EEG medical devices and proprietary biomarkers for objective assessment of traumatic brain injury (brain bleeds and concussions) at the point of care. Its flagship product, BrainScope One, pairs a ruggedized handheld EEG capture device and disposable electrode headsets with on-device algorithms (Structural Injury Classifier, Concussion Index, Brain Function Index). The company also operates a Large Neural Model deep learning platform extending LLM-style architectures to EEG to develop biomarkers across CNS indications including Alzheimer's disease prediction, stroke, and ARIA monitoring.
Is BrainScope a public or private company?
BrainScope is a private company. It is classified as venture growth investor backed and is currently operating.
When was BrainScope founded?
BrainScope was founded in 2010. It employs 11 to 50 people.
Where is BrainScope based?
BrainScope is headquartered in Bethesda, United States, in the North America region.
How does BrainScope make money?
Three revenue lines are on record. Hardware sales of BrainScope EEG device (Equipment) is the primary driver. The others are consumables: disposable electrode headsets and extended warranty and post-sale support.
Who are BrainScope's main competitors?
Direct peers on record are Ceribell and Wave Neuroscience (formerly Mind Research Network / Neuropathix). Broad incumbents are Natus Medical, Compumedics, Cadwell Industries, Medtronic, GE HealthCare and Philips (Royal Philips). Emerging players are iRhythm Technologies and Emotiv.
Does BrainScope have an API?
No public API is recorded for BrainScope.
What industry is BrainScope in?
BrainScope's product category is EEG-based Brain Injury Diagnostic Medical Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLALAGAC, Neurology Telemedicine Platforms. Its NAICS code is 334510 and its SIC code is 3845.